Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MMP2 | P08253 | 3/20 | 0.42 |
| ▸ | ANPEP | P15144 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PEPD | P12955 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2608451 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MMP2ANPEPATMCYP3A4 | |
| SCHEMBL13661911 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MMP2ANPEPATMCYP3A4 | |
| SCHEMBL16376157 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MMP2ANPEPATMCYP3A4 | |
| SCHEMBL18084393 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MMP2ANPEPATMCYP3A4 | |
| SCHEMBL26379162 | 0.86 | PEPD (0.41) | ALDH1A1MMP2ANPEPCYP3A4MAPT | |
| SCHEMBL9969991 | 0.83 | ALDH1A1 (0.40) | ALDH1A1MMP2ANPEPCYP3A4MAPT | |
| SCHEMBL13920579 | 0.82 | KMT2A (0.34) | ALDH1A1ATMCYP3A4MAPTMEN1 | |
| SCHEMBL13920501 | 0.82 | DPP4 (0.35) | ALDH1A1ATM | |
| SCHEMBL18084388 | 0.81 | MMP2 (0.38) | ALDH1A1MMP2ANPEPCYP3A4MAPT | |
| SCHEMBL12795646 | 0.81 | MMP2 (0.38) | ALDH1A1MMP2ANPEPPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312473-A1 | PROCESS FOR THE PREPARATION OF BIHETEROARYL COMPOUNDS AND CRYSTAL FORMS THEREOF | GENENTECH, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-20160067302-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-8435984-B2 | Tertiary amine substituted peptides useful as inhibitors of HCV replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8163736-B2 | Cytotoxic agents comprising new tomaymycin derivatives | SANOFI-AVENTIS (FR) | 2012-04-24 | — | — | US | disclosed |
| US-20100292219-A1 | TERTIARY AMINE SUBSTITUTED PEPTIDES USEFUL AS INHIBITORS OF HCV REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-7576089-B2 | 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION | 2009-08-18 | — | — | US | disclosed |
| US-20090036431-A1 | Cytotoxic Agents Comprising New Tomaymycin Derivatives | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067302-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, CTRB1 | ALDH1A1 769/4885MMP2 1627/4885ANPEP 1328/4885 |
| US-20090036431-A1 | Cytotoxic Agents Comprising New Tomaymycin Derivatives | TOMM70, TOMM34, TOMM40 | ALDH1A1 4617/4885MMP2 1723/4885ANPEP 1528/4885 |
| US-20100292219-A1 | TERTIARY AMINE SUBSTITUTED PEPTIDES USEFUL AS INHIBITORS OF HCV REPLICATION | RTF2, RFC5, EIF2AK2 | ALDH1A1 2021/4885MMP2 2521/4885ANPEP 64/4885 |
| US-20230312473-A1 | PROCESS FOR THE PREPARATION OF BIHETEROARYL COMPOUNDS AND CRYSTAL FORMS THEREOF | NONO, PNPO, KMO | ALDH1A1 1143/4885MMP2 4081/4885ANPEP 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.